J&J moves forward with next-gen insulin delivery

Johnson & Johnson's ($JNJ) Animas is progressing with its investigational artificial pancreas--an insulin-delivery device that can detect blood glucose in the body and automatically normalize levels. The company is plotting a second feasibility study of the platform on the heels of positive results from a trial of 13 adult patients with Type 1 diabetes, its CMO told FierceMedicalDevices. But J&J isn't the only game in town. With rates of diabetes on the rise in the U.S. and abroad, drug delivery companies and devicemakers are working to develop next-generation insulin-delivery technologies, with big guns like Medtronic ($MDT) creating a combination glucose monitor/insulin pump and smaller companies like Transdermal Specialties developing a needle-free insulin patch. Report

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…